G-CSF mobilized apheresis as an alternative source of CAR T-cells

Whether CART cells can be manufactured from recombinant human granulocyte colony stimulating factor (rhG-CSF) mobilized products, such as those that are cryopreserved for a planned hematopoietic stem cell transplant (HSCT), remains unknown.

Production of CART cells from G-CSF mobilized material would be particularly beneficial in settings where CART cells are paired with a HSCT platform, including in the context of acute myeloid leukemia (AML) as we have recently shown. We therefore compared the phenotype and function of CAR T-cells manufactured from paired samples obtained from blood before or after rhG-CSF exposure in healthy volunteer donors, to test the hypothesis that rhG-CSF mobilized CAR T-cells (mobCAR) are functionally equivalent to steady state CAR T-cells (ssCAR).